GlassScriptPhysician profile
Ayman Akkad
NPI 1841207412
$2,148.73
in general payments reported to CMS, 2019-2025
25 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $285 · 2021: $179 · 2022: $549 · 2023: $123 · 2024: $381 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.07 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $497.76 | 2021-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $371.09 | 2022-2025 | Yorvipath |
| Amgen INC. | $167.76 | 2021-2025 | Tepezza |
| Medtronic Minimed, INC. | $142.48 | 2019-2020 | |
| Corcept Therapeutics | $128.59 | 2020-2024 | Korlym |
| Novo Nordisk INC | $118.56 | 2020-2024 | Sogroya |
| Madrigal Pharmaceuticals | $115.10 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $96.00 | 2022 | |
| Pfizer INC. | $83.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $68.53 | 2019 | |
| Tandem Diabetes Care, INC. | $57.82 | 2020 | |
| Endo Pharmaceuticals INC. | $36.15 | 2019 | |
| Nevro Corp. | $31.58 | 2023 | Senza |
| Eton Pharmaceuticals, INC. | $24.87 | 2025 | Alkindi, Increlex, Khindivi |
| Amphastar Pharmaceuticals, INC. | $24.75 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23.79 | 2020 | |
| Neurocrine Biosciences, INC. | $23.59 | 2025 | |
| Lilly USA, LLC | $23.42 | 2019 | |
| Biomarin Pharmaceutical INC. | $17.94 | 2021 | |
| Gilead Sciences, INC. | $17.58 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.37 | 2021 | |
| Boston Scientific Corporation | $16.84 | 2024 | |
| Horizon Therapeutics Plc | $15.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.64 | 2023 | Unithroid |
| Ferring Pharmaceuticals INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Akkad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.